These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11794 related articles for article (PubMed ID: 10526667)
1. A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute. Touloukian CE; Rosenberg SA Cancer J Sci Am; 1999; 5(5):269-74. PubMed ID: 10526667 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094 [TBL] [Abstract][Full Text] [Related]
3. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma. Richtig E; Ludwig R; Kerl H; Smolle J Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711 [TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220 [TBL] [Abstract][Full Text] [Related]
8. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370 [TBL] [Abstract][Full Text] [Related]
9. Bolus high dose interleukin-2 for the treatment of malignant melanoma. Pappo I; Lotem M; Klein M; Orda R Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372 [TBL] [Abstract][Full Text] [Related]
10. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073 [TBL] [Abstract][Full Text] [Related]
11. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603 [TBL] [Abstract][Full Text] [Related]
12. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M; Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206 [TBL] [Abstract][Full Text] [Related]
13. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; AnzĂ M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758 [TBL] [Abstract][Full Text] [Related]
14. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G; Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225 [TBL] [Abstract][Full Text] [Related]
15. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825 [TBL] [Abstract][Full Text] [Related]
16. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362 [TBL] [Abstract][Full Text] [Related]
17. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757 [TBL] [Abstract][Full Text] [Related]
18. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma]. Kretschmer L; Helmbold P; Emmert S; Marsch WC Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468 [TBL] [Abstract][Full Text] [Related]
20. Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America. Sutherland CM; Chmiel JS; Henson DE; Winchester DP J Am Coll Surg; 1994 Nov; 179(5):561-6. PubMed ID: 7952459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]